Chemoradiation — Combined Cancer Therapy

Chemoradiation is the concurrent administration of cytotoxic chemotherapy and ionising radiation to a defined anatomical region. The primary pharmacological principle is radiosensitisation: specific chemotherapy agents inhibit tumour cells' capacity to repair radiation-induced sublethal DNA strand breaks, arrest cells in radiosensitive phases of the cell cycle, and decrease tumour hypoxia, thereby amplifying the destructive biological impact of radiation beams.

This treatment modality can be deployed in curative, neoadjuvant, adjuvant, or definitive clinical settings. In definitive protocols, chemoradiation provides organ-preserving alternatives to radical surgery. In neoadjuvant settings, it shrinks locally advanced tumours to improve surgical resectability and decrease microscopic margin involvement. However, concurrent administration also compounds acute normal tissue toxicities, requiring rigorous multidisciplinary supportive care.

Chemoradiation represents a definitive curative strategy for many cancers that cannot be removed by surgery alone, or where surgery would cause significant functional loss. For example, it often allows patients with throat, anal, or cervical cancers to preserve normal organ function without having their vocal cords, bowel, or pelvic organs surgically removed. Understanding how chemoradiation works helps patients prepare for the combined treatment schedule and manage the expected, temporary increase in acute side effects.

Before starting chemoradiation, extensive staging tests determine if concurrent therapy is appropriate. Imaging tests—including PET-CT, MRI, and diagnostic CT scans—accurately map tumour boundaries and radiation target volumes. Biomarkers such as HPV/p16 status in head and neck cancers or mismatch repair (MMR/MSI) testing in rectal cancers guide clinical decision-making. Baseline renal, liver, and haematological blood panels confirm a patient's physiological fitness for concurrent cytotoxic drugs.

Chemoradiation is a gold-standard approach in several locally advanced malignancies. It is standard definitive care in locally advanced cervical cancer, anal cancer, and head and neck squamous cell carcinomas (such as nasopharyngeal and oropharyngeal cancers). It is also widely used as neoadjuvant or definitive therapy in locally advanced oesophageal, rectal, and non-small cell lung cancers.

Chemoradiation typically pairs daily external beam radiation therapy with weekly or tri-weekly doses of radiosensitising chemotherapy (such as cisplatin, carboplatin, fluorouracil, or capecitabine). Because toxicity is heightened, proactive management is critical. Patients receive intensive symptom relief, including prophylactic anti-nausea medication, pain management, nutritional support via feeding tubes if swallowing is impaired, and dedicated skin care to manage radiation dermatitis.